Review of the PRIODAC project on thyroid protection from radioactive iodine by repeated iodide intake in individuals aged 12+

Author:

Martin Jean-Charles1ORCID,Pourcher Thierry2,Phan Guillaume3,Guglielmi Julien2,Crambes Caroline4,Caire-Maurisier François4,Lebsir Dalila3,Cohen David3,Rosique Clément1,Jing Lun2ORCID,Hichri Maha2,Salleron Lisa2,Darcourt Jacques2,Souidi Maamar3,Benderitter Marc3

Affiliation:

1. Centre de recherche en CardioVasculaire et Nutrition (C2VN), Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), Institut National pour la Santé Et la Recherche Médicale (INSERM), Aix Marseille Université (AMU), Marseille, France

2. Transporter in Imaging and Radiotherapy in Oncology Laboratory (TIRO), Direction de la Recherche Fondamentale (DRF), Institut des sciences du vivant Frederic Joliot, Commissariat à l’Energie Atomique et aux Energies alternatives (CEA), Université Côte d’Azur (UCA), School of Medicine, Nice, France

3. Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-Santé, Fontenay-aux-Roses, France

4. Pharmacie Centrale des Armées (PCA), Direction des Approvisionnements en produits de Santé des Armées, Fleury-les-Aubrais, France

Abstract

Background Intake of potassium iodide (KI) reduces the accumulation of radioactive iodine in the thyroid gland in the event of possible contamination by radioactive iodine released from a nuclear facility. The World Health Organization (WHO) has stated the need for research for optimal timing, appropriate dosing regimen, and safety for repetitive iodine thyroid blocking (ITB). The French PRIODAC project, addressed all these issues, involving prolonged or repeated releases of radioactive iodine. Preclinical studies established an effective dose through pharmacokinetic modeling, demonstrating the safety of repetitive KI treatment without toxicity. Summary Recent preclinical studies have determined an optimal effective dose for repetitive administration, associated with pharmacokinetic modeling. The results show the safety and absence of toxicity of repetitive treatment with KI. Good laboratory practice level preclinical studies corresponding to individuals >12 years have shown a safety margin established between animal doses without toxic effect. After approval from the French health authorities, the market authorization of the two tablets of KI, 65 mg/day, was defined with a new dosing scheme of a daily repetitive intake of the treatment up to 7 days unless otherwise instructed by the competent authorities for all categories of population except pregnant women and children under the age of 12 years. Conclusion This new marketed authorization resulting from scientific-based evidence obtained as part of the PRIODAC project may serve as an example to further harmonize the application of KI for repetitive ITB in situations of prolonged radioactive release at the European and international levels, under the umbrella of the WHO.

Publisher

Bioscientifica

Reference53 articles.

1. Multiple administrations of stable iodide protect population chronically exposed to radioactive iodine: what is priodac research program (2014-22) teaching us?;Benderitter,2018

2. Radiation-related thyroid cancer;Saenko,2024

3. Protection of the Human E. Guidelines for Iodine Prophylaxis Following Nuclear Accidents: Update 1999,1999

4. Protecting the thyroid in times of conflict (Ukraine 2022);Toft,2022

5. From the molecular characterization of iodide transporters to the prevention of radioactive iodide exposure;Dayem,2006

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3